Loading...

Hossein Jadvar, MD, PhD

TitleAssociate Professor of Radiology
InstitutionUniversity of Southern California
DepartmentRadiology
AddressCSC 102
Health Sciences Campus
Los Angeles CA 90089-9061
Phone+1 323 442 1107
vCardDownload vCard
    Other Positions
    TitleDirector of Radiology Research


    Collapse Biography 
    Collapse Awards and Honors
    NIH1994NIH Resident Research Award
    Radiological Society of North America1997Roentgen Resident/Fellow Research Award
    American College of Nuclear Physicians (ACNP)1998Resident Research Award
    Society of Nuclear Medicine2000 Marc Tetalman Young Investigator Award
    American College of Nuclear Medicine (ACNM)2003Fellow
    IEEE-Engineering in Medicine and Biology Society2006 Senior Member
    USC Center for Excellence in Research2007  - 2010Inaugural Faculty Fellow
    PET Clinics and Theranostics (Prostate Cancer)2009Invited Guest Editor
    35th Annual Western Regional Society of Nuclear Medicine2010Distinguished Scientist Award
    Pasadena Magazine2010  - 2013San Gabriel Valley Top Doctors
    2013Best Doctors in America
    Academy of Radiology Research2014Distinguished Investigator Award
    Journal of Nuclear Medicine (Supplement on Prostate Cancer)2016Invited Guest Editor
    Society of Nuclear Medicine and Molecular Imaging (SNMMI)2016Fellow
    World Association of Radiopharmacutical and Molecular Therapy (WARMTH)2016Prof. Ajit Padhy Memorial Oration Award

    Collapse Overview 
    Collapse Overview
    Hossein Jadvar, MD, PhD, MPH, MBA, FACNM, FSNMMI
    Associate Professor of Radiology
    Associate Professor of Biomedical Engineering
    University of Southern California, Los Angeles, CA USA
    Past President, American College of Nuclear Medicine (ACNM)
    Past President, Society of Nuclear Medicine and Molecular Imaging (SNMMI)

    Dr. Jadvar is a tenured associate professor of radiology (Keck School of Medicine) and biomedical engineering (Viterbi School of Engineering) at the University of Southern California (USC) with hospital appointments at the USC Keck Medical Center, USC Norris Comprehensive Cancer Center, and the LAC+USC Medical Center. He also served as a visiting associate in bioengineering at the California Institute of Technology in Pasadena, Calif. Dedicated to lifelong learning, Dr. Jadvar received his BS in chemical engineering from Iowa State University in Ames, Iowa, in 1982, followed by a MS in biomedical engineering from the University of Wisconsin in Madison, Wis., in 1984, and a MS in computer engineering, as well as a PhD in bioengineering, from the University of Michigan in Ann Arbor, Mich., in 1986 and 1988, respectively. He then attended the University of Chicago Pritzker School of Medicine in Chicago, Ill., for his MD degree (1993). He received his MPH degree from Harvard University in Cambridge, Mass., in 2005 and an Executive MBA from the University of Southern California in Los Angeles, Calif., in 2007. He was a clinical fellow in positron emission tomography with the Harvard Medical School Joint Program in Nuclear Medicine, in Boston, Mass., during 1998-99; a diagnostic radiology and nuclear medicine resident at Stanford University, in Stanford, Calif., during 1994-98; and an intern in internal medicine at the University of California San Francisco, Calif., during 1993-94. He has also completed a number of executive educational certificate programs at Harvard Medical School in Boston, Mass., the University of Cambridge in the UK, the University of Oxford in the UK, and the Wharton School of Business at the University of Pennsylvania in Philadelphia, Penn. Dr. Jadvar is on the editorial boards of the Journal of Nuclear Medicine, the European Journal of Nuclear Medicine and Molecular Imaging, Molecular Imaging and Biology, Radiology (Consultant to the Editor), American Journal of Roengenology (Assistant Editor), and Clinical Nuclear Medicine (Deputy Editor), and many others. He is the past president of the American College of Nuclear Medicine (ACNM) and the past recipient of the SNMMI Mark Tetalman Young Investigator Award, the Western Regional SNMMI Distinguished Scientist Award, the Academy of Radiology Research Distinguished Investigator Award, and the inaugural Prof. Ajit Padhy Oration Memorial Award from the World Association of Radiopharmaceuticals and Molecular Therapy (WARMTH), and the USC Excellence in Mentoring Award. He is a National Institutes of Health (NIH) funded investigator and serves on multiple NIH review panels (with one term as a chartered member), Department of Defense, and the Imaging Technology and Informatics Peer Review Panel of the Cancer Prevention and Research Institute of Texas (CPRIT). He is a fellow of ACNM, SNMMI, and the USC Center for Excellence in Research. He is an established nuclear medicine expert for the International Atomic Energy Agency (IAEA). He has written more than 120 journal articles, has published 4 books, 28 book chapters, 9 patents and has given more than 250 invited speaker presentations and visiting professorships at numerous national and international venues. His research interests include applications of PET in clinical outcome research and in translational molecular imaging research with particular current interest in prostate cancer. (http://www-hsc.usc.edu/~jadvar)


    Collapse Research 
    Collapse Research Activities and Funding
    Pilot Human Studies of FMAU PET in Prostate Cancer
    NIH/NIBIB R21EB017568Sep 4, 2015 - Jun 30, 2017
    Role: Principal Investigator
    [F18]FMAU in Prostate Cancer
    NIH/NCI R21CA142426Sep 1, 2009 - Aug 31, 2012
    Role: Principal Investigator
    FDG PET-CT in Metastatic Prostate Cancer
    NIH/NCI R01CA111613Aug 12, 2005 - Dec 31, 2013
    Role: Principal Investigator

    Collapse ORNG Applications 
    Collapse Websites
    Collapse Required Scholarly Project Mentor

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
    List All   |   Timeline
    1. Gholamrezanezhad A, Basques K, Batouli A, Matcuk G, Alavi A, Jadvar H. Clinical Nononcologic Applications of PET/CT and PET/MRI in Musculoskeletal, Orthopedic, and Rheumatologic Imaging. AJR Am J Roentgenol. 2018 Jun; 210(6):W245-W263. PMID: 29787313.
      View in: PubMed
    2. Chau A, Gardiner P, Colletti PM, Jadvar H. Diagnostic Performance of 18F-Fluciclovine in Detection of Prostate Cancer Bone Metastases. Clin Nucl Med. 2018 May 14. PMID: 29762238.
      View in: PubMed
    3. Varghese B, Velez E, Desai B, Jadvar H. Incidental Detection of Meningioma by 18F-FMAU PET/CT in a Patient With Suspected Prostate Cancer. Clin Nucl Med. 2018 May 07. PMID: 29742600.
      View in: PubMed
    4. Jadvar H, Colletti PM. 18F-NaF/223RaCl2 theranostics in metastatic prostate cancer: treatment response assessment and prediction of outcome. Br J Radiol. 2018 Apr 16; 20170948. PMID: 29630398.
      View in: PubMed
    5. Graham MM, Delbeke D, Jadvar H. Point: The Existential Threat to Nuclear Medicine. J Am Coll Radiol. 2018 Mar; 15(3 Pt A):384-386. PMID: 29502649.
      View in: PubMed
    6. Jadvar H, Chen X, Cai W, Mahmood U. Radiotheranostics in Cancer Diagnosis and Management. Radiology. 2018 02; 286(2):388-400. PMID: 29356634.
      View in: PubMed
    7. Delgado-Bolton R, Esposito G, Colletti PM, Jadvar H. Reply: Staging, Restaging, and Treatment Response Assessment in Lymphomas: What We Should Know. J Nucl Med. 2018 Apr; 59(4):715-716. PMID: 29419476.
      View in: PubMed
    8. Jadvar H. The First Theranostic Conference at the American University of Beirut Medical Center. J Nucl Med. 2018 Jan; 59(1):13N. PMID: 29295944.
      View in: PubMed
    9. Jadvar H. SNMMI Scientific Delegation to Cuba. J Nucl Med. 2018 Jan; 59(1):15N. PMID: 29295946.
      View in: PubMed
    10. Rahbar K, Afshar-Oromieh A, Jadvar H, Ahmadzadehfar H. PSMA Theranostics: Current Status and Future Directions. Mol Imaging. 2018 Jan-Dec; 17:1536012118776068. PMID: 29873291.
      View in: PubMed
    11. Baratto L, Jadvar H, Iagaru A. Prostate Cancer Theranostics Targeting Gastrin-Releasing Peptide Receptors. Mol Imaging Biol. 2017 Dec 18. PMID: 29256046.
      View in: PubMed
    12. Jadvar H, Ballas LK. PSMA PET: Transformational Change in Prostate Cancer Management? J Nucl Med. 2018 Feb; 59(2):228-229. PMID: 29242400.
      View in: PubMed
    13. Gholamrezanezhad A, Basques K, Batouli A, Olyaie M, Matcuk G, Alavi A, Jadvar H. Non-oncologic Applications of PET/CT and PET/MR in Musculoskeletal, Orthopedic, and Rheumatologic Imaging: General Considerations, Techniques, and Radiopharmaceuticals. J Nucl Med Technol. 2017 Nov 10. PMID: 29127246.
      View in: PubMed
    14. Jaffee EM, Dang CV, Agus DB, Alexander BM, Anderson KC, Ashworth A, Barker AD, Bastani R, Bhatia S, Bluestone JA, Brawley O, Butte AJ, Coit DG, Davidson NE, Davis M, DePinho RA, Diasio RB, Draetta G, Frazier AL, Futreal A, Gambhir SS, Ganz PA, Garraway L, Gerson S, Gupta S, Heath J, Hoffman RI, Hudis C, Hughes-Halbert C, Ibrahim R, Jadvar H, Kavanagh B, Kittles R, Le QT, Lippman SM, Mankoff D, Mardis ER, Mayer DK, McMasters K, Meropol NJ, Mitchell B, Naredi P, Ornish D, Pawlik TM, Peppercorn J, Pomper MG, Raghavan D, Ritchie C, Schwarz SW, Sullivan R, Wahl R, Wolchok JD, Wong SL, Yung A. Future cancer research priorities in the USA: a Lancet Oncology Commission. Lancet Oncol. 2017 Nov; 18(11):e653-e706. PMID: 29208398.
      View in: PubMed
    15. Jadvar H, Colletti PM, Delgado-Bolton R, Esposito G, Krause BJ, Iagaru AH, Nadel H, Quinn DI, Rohren E, Subramaniam RM, Zukotynski K, Kauffman J, Ahuja S, Griffeth L. Appropriate Use Criteria for 18F-FDG PET/CT in Restaging and Treatment Response Assessment of Malignant Disease. J Nucl Med. 2017 Dec; 58(12):2026-2037. PMID: 29025980.
      View in: PubMed
    16. Jadvar H. Highlights of articles published in annals of nuclear medicine 2016. Eur J Nucl Med Mol Imaging. 2017 Oct; 44(11):1928-1933. PMID: 28752226.
      View in: PubMed
    17. Jadvar H. The Use of Imaging in the Prediction and Assessment of Cancer Treatment Toxicity. Diagnostics (Basel). 2017 Jul 20; 7(3). PMID: 28726731.
      View in: PubMed
    18. Yoon J, Ballas L, Desai B, Jadvar H. Prostate-Specific Antigen and Prostate-Specific Antigen Kinetics in Predicting 18F-Sodium Fluoride Positron Emission Tomography-Computed Tomography Positivity for First Bone Metastases in Patients with Biochemical Recurrence after Radical Prostatectomy. World J Nucl Med. 2017 Jul-Sep; 16(3):229-236. PMID: 28670183.
      View in: PubMed
    19. Subramaniam RM, Jadvar H, Colletti PM, Guimaraes A, Gullapali R, Iagaru AH, McConathy J, Meltzer CC, Nadel H, Noto RB, Packard AB, Rohren EM, Oates ME. ACR and SNMMI Joint Credentialing Statement for PET/MRI of the Body. J Nucl Med. 2017 Jul; 58(7):1174-1176. PMID: 28473601.
      View in: PubMed
    20. Jadvar H. Targeted Radionuclide Therapy: An Evolution Toward Precision Cancer Treatment. AJR Am J Roentgenol. 2017 Aug; 209(2):277-288. PMID: 28463538.
      View in: PubMed
    21. Jadvar H. Multimodal Imaging in Focal Therapy Planning and Assessment in Primary Prostate Cancer. Clin Transl Imaging. 2017 Jun; 5(3):199-208. PMID: 28713796.
      View in: PubMed
    22. Dilsizian V, Jadvar H. Science to Practice: Does FDG Differentiate Morphologically Unstable from Stable Atherosclerotic Plaque? Radiology. 2017 Apr; 283(1):1-3. PMID: 28318446.
      View in: PubMed
    23. Jadvar H, Park R, Yap LP, Chen K, Hughes L, Conti P. Effect of Androgen on Normal Biodistribution of [18F]-2'-Fluoro-5-methyl-1-beta-D-arabinofuranosyluracil (18F-FMAU) in Athymic Non-tumor-bearing Male Mice. Anticancer Res. 2017 02; 37(2):475-479. PMID: 28179292.
      View in: PubMed
    24. Jadvar H. Radiotheranostics in Prostate Cancer: Introduction and Overview. J Nucl Med. 2016 Oct; 57(Suppl 3):1S-2S. PMID: 27694166.
      View in: PubMed
    25. Jadvar H. PET of Glucose Metabolism and Cellular Proliferation in Prostate Cancer. J Nucl Med. 2016 Oct; 57(Suppl 3):25S-29S. PMID: 27694167.
      View in: PubMed
    26. Iagaru AH, Mittra E, Colletti PM, Jadvar H. Bone-Targeted Imaging and Radionuclide Therapy in Prostate Cancer. J Nucl Med. 2016 Oct; 57(Suppl 3):19S-24S. PMID: 27694165.
      View in: PubMed
    27. Zukotynski K, Jadvar H, Hope T, Subramaniam RM, Van Loon K, Varma M, Niederkohr RD. SNMMI Comment on the 2016 Society of Surgical Oncology "Choosing Wisely" Recommendation on the Use of PET/CT in Colorectal Cancer. J Nucl Med. 2017 Jan; 58(1):11-12. PMID: 27688471.
      View in: PubMed
    28. Jadvar H. Is There Use for FDG-PET in Prostate Cancer? Semin Nucl Med. 2016 11; 46(6):502-506. PMID: 27825430.
      View in: PubMed
    29. Jadvar H. Pathways to the Future of Nuclear Medicine Task Force: Phase 1 Report. J Nucl Med. 2016 Sep; 57(9):17N-9N. PMID: 27587796.
      View in: PubMed
    30. Gulati M, Palmer SL, Im MY, Jadvar H, Qazi YA, Fazli U, Grant EG. Duplex Doppler sonography: is there clinical relevance to elevated renal vein velocity in kidney transplants? Clin Imaging. 2016 Nov - Dec; 40(6):1237-1245. PMID: 27618805.
      View in: PubMed
    31. Kitajima K, Yamamoto S, Fukushima K, Minamimoto R, Kamai T, Jadvar H. Update on advances in molecular PET in urological oncology. Jpn J Radiol. 2016 Jul; 34(7):470-85. PMID: 27222021.
      View in: PubMed
    32. Zukotynski K, Jadvar H, Capala J, Fahey F. Targeted Radionuclide Therapy: Practical Applications and Future Prospects. Biomark Cancer. 2016; 8(Suppl 2):35-8. PMID: 27226737; PMCID: PMC4874742.
    33. Jadvar H. Positron emission tomography in imaging evaluation of staging, restaging, treatment response, and prognosis in prostate cancer. Abdom Radiol (NY). 2016 05; 41(5):889-98. PMID: 27193789.
      View in: PubMed
    34. Jadvar H. SNMMI Leadership Update: Pathways to the Future of Nuclear Medicine. J Nucl Med. 2016 Apr; 57(4):15N. PMID: 27037354.
      View in: PubMed
    35. Jadvar H. SNMMI Leadership Update: Developing Evidence-Based Appropriate Use Criteria under the Protecting Access to Medicare Act of 2014. J Nucl Med. 2015 Nov; 56(11):20N. PMID: 26526797.
      View in: PubMed
    36. Jadvar H. Positron Emission Tomography in Prostate Cancer: Summary of Systematic Reviews and Meta-Analysis. Tomography. 2015 Sep; 1(1):18-22. PMID: 26726317.
      View in: PubMed
    37. Jadvar H, Chen K, Ukimura O. Targeted Prostate Gland Biopsy With Combined Transrectal Ultrasound, mpMRI, and 18F-FMAU PET/CT. Clin Nucl Med. 2015 Aug; 40(8):e426-8. PMID: 26018690; PMCID: PMC4494895.
    38. Fahey F, Zukotynski K, Jadvar H, Capala J. Proceedings of the Second NCI-SNMMI Workshop on Targeted Radionuclide Therapy. J Nucl Med. 2015 Jul; 56(7):1119-29. PMID: 25999432.
      View in: PubMed
    39. Jadvar H. PSMA PET in Prostate Cancer. J Nucl Med. 2015 Aug; 56(8):1131-2. PMID: 25977465.
      View in: PubMed
    40. Jadvar H, Challa S, Quinn DI, Conti PS. One-Year Postapproval Clinical Experience with Radium-223 Dichloride in Patients with Metastatic Castrate-Resistant Prostate Cancer. Cancer Biother Radiopharm. 2015 Jun; 30(5):195-9. PMID: 25746633; PMCID: PMC4492702.
    41. Jadvar H, Subramaniam RM, Berman CG, Boada F, Colletti PM, Guimaraes AR, McConathy J, Meltzer CC, Noto RB, Packard AB, Rohren EM, Oates ME. American College of Radiology and Society of Nuclear Medicine and Molecular Imaging Joint Credentialing Statement for PET/MR Imaging: Brain. J Nucl Med. 2015 Apr; 56(4):642-5. PMID: 25745088; PMCID: PMC4465538.
    42. Jadvar H, Groshen SG, Quinn DI. Association of overall survival with glycolytic activity of castrate-resistant prostate cancer metastases. Radiology. 2015 Feb; 274(2):624-5. PMID: 25625748.
      View in: PubMed
    43. Jadvar H. Prognostic Utility of PET in Prostate Cancer. PET Clin. 2015 Apr; 10(2):255-63. PMID: 25829090; PMCID: PMC4382583.
    44. Jadvar H, Desai B, Conti PS. Sodium 18F-fluoride PET/CT of bone, joint, and other disorders. Semin Nucl Med. 2015 Jan; 45(1):58-65. PMID: 25475379; PMCID: PMC4258001.
    45. Jadvar H. Imaging Cellular Proliferation in Prostate Cancer with Positron Emission Tomography. Asia Ocean J Nucl Med Biol. 2015; 3(2):72-6. PMID: 27408885; PMCID: PMC4937643.
    46. Yu CY, Desai B, Ji L, Groshen S, Jadvar H. Comparative performance of PET tracers in biochemical recurrence of prostate cancer: a critical analysis of literature. Am J Nucl Med Mol Imaging. 2014; 4(6):580-601. PMID: 25250207; PMCID: PMC4171844.
    47. Rohren EM, Dillehay GL, Jadvar H. SNMMI comment on ASCO 2013 "Choosing wisely" recommendation on use of PET/CT in recurrent cancer surveillance. J Nucl Med. 2014 May; 55(5):699-700. PMID: 24665086.
      View in: PubMed
    48. Parker JA, Christian P, Jadvar H, Sattler B, Wallis JW. The SNMMI and EANM practice guideline for tele-nuclear medicine 2.0. J Nucl Med Technol. 2014 Mar; 42(1):15-9. PMID: 24375155.
      View in: PubMed
    49. Jadvar H, Quinn DI. Targeted a-particle therapy of bone metastases in prostate cancer. Clin Nucl Med. 2013 Dec; 38(12):966-71. PMID: 24212441; PMCID: PMC3874447.
    50. Jadvar H. Molecular imaging of prostate cancer with PET. J Nucl Med. 2013 Oct; 54(10):1685-8. PMID: 24084704.
      View in: PubMed
    51. Jadvar H, Desai B, Ji L, Conti PS, Dorff TB, Groshen SG, Pinski JK, Quinn DI. Baseline 18F-FDG PET/CT parameters as imaging biomarkers of overall survival in castrate-resistant metastatic prostate cancer. J Nucl Med. 2013 Aug; 54(8):1195-201. PMID: 23785174; PMCID: PMC3783857.
    52. Jadvar H, Colletti PM. Competitive advantage of PET/MRI. Eur J Radiol. 2014 Jan; 83(1):84-94. PMID: 23791129; PMCID: PMC3800216.
    53. Jadvar H. Imaging evaluation of prostate cancer with 18F-fluorodeoxyglucose PET/CT: utility and limitations. Eur J Nucl Med Mol Imaging. 2013 Jul; 40 Suppl 1:S5-10. PMID: 23429934; PMCID: PMC3681838.
    54. Jadvar H, Yap LP, Park R, Li Z, Chen K, Hughes L, Kouhi A, Conti P. [18F]-2'-Fluoro-5-methyl-1-beta-D-arabinofuranosyluracil (18F-FMAU) in prostate cancer: initial preclinical observations. Mol Imaging. 2012 Sep-Oct; 11(5):426-32. PMID: 22954187; PMCID: PMC3443080.
    55. Jadvar H. Molecular imaging of prostate cancer: PET radiotracers. AJR Am J Roentgenol. 2012 Aug; 199(2):278-91. PMID: 22826388; PMCID: PMC3408965.
    56. Silberstein EB, Alavi A, Balon HR, Clarke SE, Divgi C, Gelfand MJ, Goldsmith SJ, Jadvar H, Marcus CS, Martin WH, Parker JA, Royal HD, Sarkar SD, Stabin M, Waxman AD. The SNMMI practice guideline for therapy of thyroid disease with 131I 3.0. J Nucl Med. 2012 Oct; 53(10):1633-51. PMID: 22787108.
      View in: PubMed
    57. Jadvar H. Hepatocellular carcinoma and gastroenteropancreatic neuroendocrine tumors: potential role of other positron emission tomography radiotracers. Semin Nucl Med. 2012 Jul; 42(4):247-54. PMID: 22681673.
      View in: PubMed
    58. Jadvar H, Desai B, Ji L, Conti PS, Dorff TB, Groshen SG, Gross ME, Pinski JK, Quinn DI. Prospective evaluation of 18F-NaF and 18F-FDG PET/CT in detection of occult metastatic disease in biochemical recurrence of prostate cancer. Clin Nucl Med. 2012 Jul; 37(7):637-43. PMID: 22691503; PMCID: PMC3375600.
    59. Xie J, Wang GJ, Yow L, Humayun MS, Weiland JD, Cela CJ, Jadvar H, Lazzi G, Dhrami-Gavazi E, Tsang SH. Preservation of retinotopic map in retinal degeneration. Exp Eye Res. 2012 May; 98:88-96. PMID: 22685713; PMCID: PMC4310463.
    60. Jadvar H. Can Choline PET Tackle the Challenge of Imaging Prostate Cancer? Theranostics. 2012; 2(3):331-2. PMID: 22448199; PMCID: PMC3311231.
    61. Desai B, Elatre W, Quinn DI, Jadvar H. FDG PET/CT demonstration of pancreatic metastasis from prostate cancer. Clin Nucl Med. 2011 Oct; 36(10):961-2. PMID: 21892064; PMCID: PMC3167095.
    62. Jadvar H. Colonic FDG uptake pattern in subjects receiving oral contrast with no known or suspected colonic disease. Clin Nucl Med. 2011 Sep; 36(9):754-6. PMID: 21825842.
      View in: PubMed
    63. Henkin RE, Del Rowe JD, Grigsby PW, Hartford AC, Jadvar H, Macklis RM, Parker JA, Wong JY, Rosenthal SA. ACR-ASTRO practice guideline for the performance of therapy with unsealed radiopharmaceutical sources. Clin Nucl Med. 2011 Aug; 36(8):e72-80. PMID: 21716005.
      View in: PubMed
    64. Jadvar H. Prostate cancer. Methods Mol Biol. 2011; 727:265-90. PMID: 21331939.
      View in: PubMed
    65. Jadvar H. Prostate cancer: PET with 18F-FDG, 18F- or 11C-acetate, and 18F- or 11C-choline. J Nucl Med. 2011 Jan; 52(1):81-9. PMID: 21149473; PMCID: PMC3012154.
    66. Yu F, Huang J, Adlerz K, Jadvar H, Hamdan MH, Chi N, Chen JN, Hsiai TK. Evolving cardiac conduction phenotypes in developing zebrafish larvae: implications to drug sensitivity. Zebrafish. 2010 Dec; 7(4):325-31. PMID: 20958244; PMCID: PMC3005146.
    67. Xie J, Wang GJ, Yow L, J Cela C, Humayun MS, Weiland JD, Lazzi G, Jadvar H. Modeling and percept of transcorneal electrical stimulation in humans. IEEE Trans Biomed Eng. 2011 Jul; 58(7):1932-9. PMID: 20952323.
      View in: PubMed
    68. Lin E, Wang Q, Swenson S, Jadvar H, Groshen S, Ye W, Markland FS, Pinski J. The disintegrin contortrostatin in combination with docetaxel is a potent inhibitor of prostate cancer in vitro and in vivo. Prostate. 2010 Sep 01; 70(12):1359-70. PMID: 20623636.
      View in: PubMed
    69. Jadvar H. Influence of trigger PSA and PSA kinetics on (11)C-choline PET/CT detection rate in patients with biochemical relapse after radical prostatectomy. J Nucl Med. 2010 Mar; 51(3):498-9; author reply 499-500. PMID: 20150273.
      View in: PubMed
    70. Jadvar H, Alavi A, Gambhir SS. 18F-FDG uptake in lung, breast, and colon cancers: molecular biology correlates and disease characterization. J Nucl Med. 2009 Nov; 50(11):1820-7. PMID: 19837767; PMCID: PMC2783751.
    71. Jadvar H. Molecular imaging of prostate cancer with 18F-fluorodeoxyglucose PET. Nat Rev Urol. 2009 Jun; 6(6):317-23. PMID: 19434102; PMCID: PMC2734968.
    72. Jadvar H, Alavi A. Role of Imaging in Prostate Cancer. PET Clin. 2009 Apr 01; 4(2):135-8. PMID: 20161047.
      View in: PubMed
    73. Jadvar H. FDG PET in Prostate Cancer. PET Clin. 2009 Apr 01; 4(2):155-61. PMID: 20161051.
      View in: PubMed
    74. Jadvar H. Preface. PET Clin. 2009 Apr; 4(2):ix. PMID: 27157012.
      View in: PubMed
    75. Jadvar H. Molecular imaging of prostate cancer: a concise synopsis. Mol Imaging. 2009 Mar-Apr; 8(2):56-64. PMID: 19397851; PMCID: PMC2688393.
    76. Iagaru A, Kundu R, Jadvar H, Nagle D. Evaluation by 18F-FDG-PET of patients with anal squamous cell carcinoma. Hell J Nucl Med. 2009 Jan-Apr; 12(1):26-9. PMID: 19330178.
      View in: PubMed
    77. Jadvar H, Ye W, Groshen S, Conti PS. [F-18]-fluorodeoxyglucose PET-CT of the normal prostate gland. Ann Nucl Med. 2008 Nov; 22(9):787-93. PMID: 19039557; PMCID: PMC2636719.
    78. Jadvar H, Gurbuz A, Li X, Shahinian A, Conti PS. Choline autoradiography of human prostate cancer xenograft: effect of castration. Mol Imaging. 2008 May-Jun; 7(3):147-52. PMID: 19123985; PMCID: PMC2621313.
    79. Jadvar H, Quan V, Henderson RW, Conti PS. [F-18]-Fluorodeoxyglucose PET and PET-CT in diagnostic imaging evaluation of locally recurrent and metastatic bladder transitional cell carcinoma. Int J Clin Oncol. 2008 Feb; 13(1):42-7. PMID: 18307018; PMCID: PMC2295284.
    80. Jadvar H, Connolly LP, Fahey FH, Shulkin BL. PET and PET/CT in pediatric oncology. Semin Nucl Med. 2007 Sep; 37(5):316-31. PMID: 17707239.
      View in: PubMed
    81. Janne d'Othée B, Siebert U, Cury R, Jadvar H, Dunn EJ, Hoffmann U. A systematic review on diagnostic accuracy of CT-based detection of significant coronary artery disease. Eur J Radiol. 2008 Mar; 65(3):449-61. PMID: 17590554.
      View in: PubMed
    82. Jadvar H, Henderson RW, Conti PS. [F-18]fluorodeoxyglucose positron emission tomography and positron emission tomography: computed tomography in recurrent and metastatic cholangiocarcinoma. J Comput Assist Tomogr. 2007 Mar-Apr; 31(2):223-8. PMID: 17414758.
      View in: PubMed
    83. Ho L, Henderson R, Jadvar H. Adenocarcinoma in an Indiana pouch on PET-CT. Clin Nucl Med. 2007 Jan; 32(1):57-8. PMID: 17179810.
      View in: PubMed
    84. Ho L, Seto J, Jadvar H. Actinomycosis mimicking anastomotic recurrent esophageal cancer on PET-CT. Clin Nucl Med. 2006 Oct; 31(10):646-7. PMID: 16985378.
      View in: PubMed
    85. Jadvar H, Henderson RW, Conti PS. 2-deoxy-2-[F-18]fluoro-D-glucose-positron emission tomography/computed tomography imaging evaluation of esophageal cancer. Mol Imaging Biol. 2006 May-Jun; 8(3):193-200. PMID: 16565910.
      View in: PubMed
    86. Jadvar H, Bonyadlou S, Iagaru A, Colletti PM. FDG PET-CT demonstration of Sjogren's sialoadenitis. Clin Nucl Med. 2005 Oct; 30(10):698-9. PMID: 16166849.
      View in: PubMed
    87. Jadvar H, Xiankui L, Shahinian A, Park R, Tohme M, Pinski J, Conti PS. Glucose metabolism of human prostate cancer mouse xenografts. Mol Imaging. 2005 Apr-Jun; 4(2):91-7. PMID: 16105512.
      View in: PubMed
    88. Jadvar H, Alavi A, Mavi A, Shulkin BL. PET in pediatric diseases. Radiol Clin North Am. 2005 Jan; 43(1):135-52. PMID: 15693653.
      View in: PubMed
    89. Jadvar H, Gamie S, Ramanna L, Conti PS. Musculoskeletal system. Semin Nucl Med. 2004 Oct; 34(4):254-61. PMID: 15493003.
      View in: PubMed
    90. Jadvar H, Conti PS. The reproductive tract. Semin Nucl Med. 2004 Oct; 34(4):262-73. PMID: 15493004.
      View in: PubMed
    91. Jadvar H, Cham D, Gamie S, Henderson RW. Fusion positron emission tomography-computed tomography demonstration of epidural metastases. Clin Nucl Med. 2004 Jan; 29(1):39-40. PMID: 14688597.
      View in: PubMed
    92. Jadvar H, Kherbache HM, Pinski JK, Conti PS. Diagnostic role of [F-18]-FDG positron emission tomography in restaging renal cell carcinoma. Clin Nephrol. 2003 Dec; 60(6):395-400. PMID: 14690256.
      View in: PubMed
    93. Jadvar H, Pinski JK, Conti PS. FDG PET in suspected recurrent and metastatic prostate cancer. Oncol Rep. 2003 Sep-Oct; 10(5):1485-8. PMID: 12883728.
      View in: PubMed
    94. Jadvar H, Tatlidil R, Garcia AA, Conti PS. Evaluation of recurrent gastric malignancy with [F-18]-FDG positron emission tomography. Clin Radiol. 2003 Mar; 58(3):215-21. PMID: 12639527.
      View in: PubMed
    95. Parker JA, Wallis JW, Jadvar H, Christian P, Todd-Pokropek A. Procedure guideline for telenuclear medicine 1.0. J Nucl Med. 2002 Oct; 43(10):1410-3. PMID: 12368381.
      View in: PubMed
    96. Jadvar H, Conti PS. Diagnostic utility of FDG PET in multiple myeloma. Skeletal Radiol. 2002 Dec; 31(12):690-4. PMID: 12483429.
      View in: PubMed
    97. Tatlidil R, Jadvar H, Bading JR, Conti PS. Incidental colonic fluorodeoxyglucose uptake: correlation with colonoscopic and histopathologic findings. Radiology. 2002 Sep; 224(3):783-7. PMID: 12202714.
      View in: PubMed
    98. Saremi F, Jadvar H, Siegel ME. Pharmacologic interventions in nuclear radiology: indications, imaging protocols, and clinical results. Radiographics. 2002 May-Jun; 22(3):477-90. PMID: 12006682.
      View in: PubMed
    99. Jadvar H, Fischman AJ. Evaluation of Rare Tumors with [F-18]Fluorodeoxyglucose Positron Emission Tomography. Clin Positron Imaging. 1999 May; 2(3):153-158. PMID: 14516539.
      View in: PubMed